The effects of lipid-lowering drugs [including statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors] on hyperlipidaemia have been established. Some may have treatment effects beyond their reported properties, offering potential opportunities for drug repurposing. Epidemiological studies have reported conflicting findings on the relationship between lipid-lowering medication use and sarcopenia risk.

中文翻译：

---

对前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型遗传代理抑制与肌肉减少症风险之间关系的新见解


降脂药物 [包括他汀类药物、依折麦布和前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型 （PCSK9） 抑制剂] 对高脂血症的影响已经确定。有些可能具有超出其报道特性的治疗效果，为药物再利用提供了潜在机会。流行病学研究报告了关于降脂药物使用与肌肉减少症风险之间关系的相互矛盾的结果。